117 related articles for article (PubMed ID: 12495908)
1. STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
Consoli U; Milone G; Guido G; Consoli C; Palumbo GA; Giustolisi R
Haematologica; 2002 Dec; 87(12):ECR37. PubMed ID: 12495908
[No Abstract] [Full Text] [Related]
2. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Wassmann B; Scheuring U; Thiede C; Pfeifer H; Bornhäuser M; Griesinger F; Hochhaus A; Schleyer E; Gschaidmeier H; Hoelzer D; Ottmann OG
Bone Marrow Transplant; 2003 Apr; 31(7):611-4. PubMed ID: 12692630
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
Au WY; Lie AK; Ma SK; Wan TS; Liang R; Chan EC; Kwong YL
Bone Marrow Transplant; 2002 Oct; 30(7):453-7. PubMed ID: 12368958
[TBL] [Abstract][Full Text] [Related]
4. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Wassmann B; Klein SA; Scheuring U; Pfeifer H; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
Bone Marrow Transplant; 2001 Oct; 28(7):721-4. PubMed ID: 11704799
[TBL] [Abstract][Full Text] [Related]
5. Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
Baron F; Frère P; Herens C; Fillet G; Beguin Y
Haematologica; 2002 Dec; 87(12):ECR43. PubMed ID: 12553332
[No Abstract] [Full Text] [Related]
6. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
7. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of chronic myelogenous leukemia in 2004].
Hochhaus A; Berger U; Hehlmann R
Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
[TBL] [Abstract][Full Text] [Related]
9. Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML.
le Coutre P; Kreuzer KA; Massenkeil G; Baskaynak G; Zschieschang P; Genvresse I; Lupberger J; Mapara M; Dörken B; Arnold R
Leukemia; 2003 Dec; 17(12):2525-6. PubMed ID: 14562118
[No Abstract] [Full Text] [Related]
10. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
11. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
12. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia].
Sugawara W; Endo M; Nakatuji Y; Hosokawa T; Chida S
Rinsho Ketsueki; 2003 Sep; 44(9):962-4. PubMed ID: 14577318
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
15. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
16. [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
Fischer T
Med Klin (Munich); 2002 Jan; 97 Suppl 1():22-7. PubMed ID: 11831068
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Kim YJ; Kim DW; Lee S; Kim YL; Hwang JY; Park YH; Kim HJ; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2004 Jan; 33(2):237-42. PubMed ID: 14628081
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
Kalayoglu-Besisik S; Ozturk GB; Caliskan Y; Nalcaci M; Gurses N; Cin N; Ozbek U; Sargin D
Transfus Apher Sci; 2007 Feb; 36(1):91-4. PubMed ID: 17222585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]